-
Gracell’s FasTCAR Platform Wins Fierce Life Sciences Innovation Award
•
China-based Gracell Biotechnologies Inc’s (Nasdaq.GRCL) FasTCAR technology platform has been named the winner of this year’s Fierce Life Sciences Innovation Award. The announcement was made by Gracell CEO William Wei Cao during the firm’s Q3 earnings conference call. The FasTCAR platform enables the “next-day manufacture” of autologous chimeric antigen receptor…
-
Walvax Biotechnology Expands Manufacturing Partnership with Etana for PCV and HPV Vaccines
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has entered into another manufacturing cooperation agreement with Indonesia-based PT Etana Biotechnologies (Etana) for PCV and HPV vaccines. This builds on an earlier agreement for Etana to provide local manufacturing of Walvax Bio’s COVID-19 mRNA vaccine in Indonesia. Financial details of the partnership…
-
Simcere Pharmaceuticals Licenses Idorsia’s Insomnia Therapy Daridorexant for Greater China
•
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced the establishment of a licensing agreement with Swiss firm Idorsia Ltd, securing exclusive development and commercialization rights to Idorsia’s insomnia therapy daridorexant in Greater China, including mainland China, Hong Kong, and Macau. The agreement also includes clinical research and development (R&D) activities.…
-
Sirnaomics Announces Key Executive Promotions Effective November 15
•
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced key changes to its C-suite, effective as of November 15, 2022. These leadership moves reflect the company’s strategic focus on growth and operational excellence. CFO PromotionYe Yongji, former China Chief Financial Officer (CFO), has been promoted to group CFO, vice-president…
-
Hengrui Pharmceuticals’ SHR0302 Achieves Positive Results in Phase III Atopic Dermatitis Study
•
China-based Jiangsu Hengrui Pharmceuticals (SHA: 600276) has announced positive results from the randomized, double-blind, placebo-controlled, multi-center RSJ10333 (QUARTZ3) Phase III study for SHR0302 in atopic dermatitis. The study, conducted by Hengrui’s subsidiary Reistone Biopharma Co., Ltd, has reached the pre-set primary efficacy endpoint. Study DetailsThe RSJ10333 study was designed to…
-
Kanghong Pharma Gains NMPA Approval for Innovative Eye Injection KH631
•
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approvals from the National Medical Products Administration (NMPA) for its Category 1 innovative eye injection KH631 and a generic version of Acadia Pharmaceuticals Inc’s pimavanserin. The approvals are for the treatment of neovascular (wet) age-related macular…
-
Antengene’s ATG-008 Shows Promising Results in Cervical Cancer and Hepatocellular Carcinoma Studies
•
Shanghai-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced positive preliminary results from the TORCH-2 study (NCT04337463) for its mTORC1/2 inhibitor ATG-008 (onatasertib) in combination with the programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) for recurrent/metastatic cervical cancer. The company also released data from the TORCH study for ATG-008 monotherapy in…
-
CStone Pharmaceuticals Launches AML Public Welfare Project with China Social Welfare Foundation
•
The acute myeloid leukemia (AML) public welfare project, initiated by the China Social Welfare Foundation (CSWF) and sponsored by CStone Pharmaceuticals (HKG: 2616), has officially been launched. This initiative aims to raise awareness and support for AML, a disease that disproportionately affects the elderly and progresses rapidly. AML ContextAcute myeloid…
